Description

Actrapid (insulin) NM Penfil solution for injections 100 IU/ml. 3 ml. cartridge №5

Ingredients:

Actrapid (insulin) NM Penfil solution for injections contains 100 IU/ml of insulin as the active ingredient. Other ingredients include glycerol, metacresol, zinc chloride, sodium hydroxide, hydrochloric acid, and water for injections.

Dosage:

The dosage of Actrapid (insulin) NM Penfil solution for injections should be individualized based on the patient’s needs. It is typically administered subcutaneously 30 minutes before a meal. Dosage adjustments may be necessary based on blood glucose monitoring.

Indications:

Actrapid (insulin) NM Penfil solution for injections is indicated for the treatment of diabetes mellitus to control high blood sugar. It helps regulate glucose levels in the body and prevent complications of diabetes.

Contraindications:

Do not use Actrapid (insulin) NM Penfil solution for injections if you are allergic to any of the ingredients, experiencing hypoglycemia, or if there are changes in the appearance of the solution. Consult a healthcare provider before use.

Directions:

Administer Actrapid (insulin) NM Penfil solution for injections as directed by a healthcare professional. Follow proper injection techniques and rotate injection sites to prevent lipodystrophy. Monitor blood glucose levels regularly.

Scientific Evidence:

Actrapid (insulin) NM Penfil solution for injections has been extensively studied in clinical trials. Research published in the Journal of Diabetes Science and Technology demonstrated the efficacy of Actrapid in controlling postprandial glucose levels in patients with diabetes type 2.

Additional Information:

It is important to store Actrapid (insulin) NM Penfil solution for injections in the refrigerator between 2°C to 8°C. Do not freeze the solution. Keep the cartridge in the outer carton to protect it from light. Always check the expiration date before use.

Pharmacological Effects: Actrapid (insulin) NM Penfil solution for injections acts by promoting the uptake of glucose into cells, thereby reducing blood sugar levels. It mimics the action of endogenous insulin and helps maintain glucose homeostasis in the body.

Clinical Trials: In a comparative study published in the Journal of Clinical Endocrinology & Metabolism, Actrapid was found to be as effective as other rapid-acting insulins in controlling postprandial glucose excursions in patients with type 1 diabetes.